All stock lists
Unlock the score
Attovia Therapeutics, Inc. (ATTO)
NASDAQ: ATTO · Real-Time Price · USD
Healthcare · Biotechnology
13.80-0.03 (-0.22%)
Insider Score
/ 100
ATTO Insider Score
Attovia Therapeutics, Inc. has a live Insider Score.
Scored on 4 qualifying trades from 1 insider in the last 90 days.
ATTO Stock Insider Trading Activity
ATTO stock’s insider trading shows 9 purchases for an estimated $65.80M and 1 sale on the open market for an estimated $29.34K by company insiders over the last 6 months.
Not enough price history.
Insider Trading Activity (Form 4 Filings)
An insider trade occurs when an individual that has non-public information about a company buys or sells shares of that company’s stock. Examples of insiders include a company’s executive officers (CEO, CFO, COO), its board of directors, and its major shareholders. Insiders are required to submit their trading activity to the SEC through Form 4 filings.
Scored window · last 90 days4 qualifying buys1 insider$72.94M bought— these are the numbers in the rankings table; the full history below shows every filing (buys, sells and older activity).
| Insider | Action | Shares | Avg Cost | Total | Δ Holdings | Held After | Date | Grade | Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| venBio Global Strategic Fund IV, L.P. Other | Buy | 382,352 | $17.00 | $6.50M | 10.1% | 4,181,367 | Aug 6, 2026 | — | Form 4 |
| WALSH COLIN Director | Converted | 478,498 | — | — | 23.4% | 2,520,632 | Aug 6, 2026 | — | Form 4 |
| WALSH COLIN Director | Buy | 500,000 | $17.00 | $8.50M | 19.8% | 3,020,632 | Aug 6, 2026 | CBig Buy | Form 4 |
| WALSH COLIN Director | Converted | 1,957,134 | — | — | 2303% | 2,042,134 | Aug 6, 2026 | — | Form 4 |
| Frazier Life Sciences XI, L.P. Other | Converted | 1,590,175 | — | — | 87.2% | 3,414,716 | Aug 6, 2026 | — | Form 4 |
| Frazier Life Sciences XI, L.P. Other | Buy | 588,235 | $17.00 | $10.00M | 10.6% | 6,154,213 | Aug 6, 2026 | — | Form 4 |
| Frazier Life Sciences XI, L.P. Other | Converted | 961,322 | — | — | 20.9% | 5,565,978 | Aug 6, 2026 | — | Form 4 |
| Frazier Life Sciences XI, L.P. Other | Converted | 1,189,940 | — | — | 34.8% | 4,604,656 | Aug 6, 2026 | — | Form 4 |
| Frazier Life Sciences XI, L.P. Other | Converted | 1,749,192 | — | — | 2321% | 1,824,541 | Aug 6, 2026 | — | Form 4 |
| GOLDMAN SACHS GROUP INC Other | Converted | 478,498 | — | — | 23.4% | 2,520,632 | Aug 6, 2026 | — | Form 4 |
| GOLDMAN SACHS GROUP INC Other | Buy | 500,000 | $17.00 | $8.50M | 19.8% | 3,020,632 | Aug 6, 2026 | — | Form 4 |
| GOLDMAN SACHS GROUP INC Other | Converted | 1,957,134 | — | — | 2303% | 2,042,134 | Aug 6, 2026 | — | Form 4 |
| Redmile Group, LLC Other | Converted | 782,854 | — | — | New | 782,854 | Aug 6, 2026 | — | Form 4 |
| Redmile Group, LLC Other | Buy | 200,000 | $17.00 | $3.40M | 25.5% | 982,854 | Aug 6, 2026 | — | Form 4 |
| Redmile Group, LLC Other | Buy | 400,000 | $17.00 | $6.80M | 51.1% | 1,182,854 | Aug 6, 2026 | — | Form 4 |
| Sanofi Other | Buy | 300,000 | $17.00 | $5.10M | 38.3% | 1,082,855 | Aug 6, 2026 | — | Form 4 |
| Sanofi Other | Converted | 782,855 | — | — | New | 782,855 | Aug 6, 2026 | — | Form 4 |
| venBio Global Strategic Fund IV, L.P. Other | Converted | 821,998 | — | — | 35.6% | 3,133,868 | Aug 6, 2026 | — | Form 4 |
| venBio Global Strategic Fund IV, L.P. Other | Converted | 2,311,870 | — | — | New | 2,311,870 | Aug 6, 2026 | — | Form 4 |
| GOLDMAN SACHS GROUP INC Other | Converted | 1,957,134 | — | — | 2303% | 2,042,134 | Aug 6, 2026 | — | Form 4 |
| GOLDMAN SACHS GROUP INC Other | Converted | 478,498 | — | — | 23.4% | 2,520,632 | Aug 6, 2026 | — | Form 4 |
| GOLDMAN SACHS GROUP INC Other | Buy | 500,000 | $17.00 | $8.50M | 19.8% | 3,020,632 | Aug 6, 2026 | — | Form 4 |
| venBio Global Strategic Fund IV, L.P. Other | Converted | 665,147 | — | — | 21.2% | 3,799,015 | Aug 6, 2026 | — | Form 4 |
| WALSH COLIN Director | Converted | 1,957,134 | — | — | 2303% | 2,042,134 | Aug 6, 2026 | — | Form 4 |
| WALSH COLIN Director | Converted | 478,498 | — | — | 23.4% | 2,520,632 | Aug 6, 2026 | — | Form 4 |
| WALSH COLIN Director | Buy | 500,000 | $17.00 | $8.50M | 19.8% | 3,020,632 | Aug 6, 2026 | CBig Buy | Form 4 |
| Deep Track Biotechnology Master Fund, Ltd. Other | Converted | 1,957,138 | — | — | New | 1,957,138 | Aug 6, 2026 | — | Form 4 |
| GOLDMAN SACHS GROUP INC Other | Sell | 1,332 | $22.03 | $29.34K | 1.6% | 82,233 | Aug 5, 2026 | — | Form 4 |
What these mean— the action is the SEC’s own Form 4 transaction code. Only a buy or a sell is an open-market trade; the rest are transfers, awards and exercises, which is why they carry no price.
- Buy (P) — Open-market or private purchase
- Sell (S) — Open-market or private sale
- Converted (C) — Conversion of a derivative security into shares
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.